Jane E. Sisk, PhD; William Whang, MD, MS; Jay C. Butler, MD; Vishnu-Priya Sneller, MBBS, PhD; Cynthia G. Whitney, MD, MPH
Acknowledgments: The authors thank the Centers for Disease Control and Prevention staff, especially Ray Strikas, Walter Williams, and Walter Orenstein, for encouragement and guidance, and James Singleton for data on immunocompromised people; the United Network for Organ Sharing for data on transplant survivors; and Marshall McBean, University of Minnesota, and the Centers for Medicare & Medicaid Services (formerly the Health Care Financing Administration) for data on Medicare payment rates.
Grant Support: This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention through the Association of Schools of Public Health, project number S343-16/16.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Jane E. Sisk, PhD, Department of Health Policy, Mount Sinai School of Medicine, Room 2-34, 1425 Madison Avenue, New York, NY 10029; e-mail, email@example.com.
Current Author Addresses: Dr. Sisk: Department of Health Policy, Mount Sinai School of Medicine, Room 2-34, 1425 Madison Avenue, New York, NY 10029.
Dr. Whang: Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114.
Dr. Butler: Centers for Disease Control and Prevention, 4055 Tudor Centre Drive, Anchorage, AK 99508.
Dr. Sneller: Centers for Disease Control and Prevention, 1600 Clifton Road, MS C-61, Atlanta, GA 30333.
Dr. Whitney: Centers for Disease Control and Prevention, 1600 Clifton Road, MS C23, Atlanta, GA 30333.
Author Contributions: Conception and design: J.E. Sisk, J.C. Butler, V.-P. Sneller.
Analysis and interpretation of the data: J.E. Sisk, W. Whang, J.C. Butler, V.-P. Sneller, C.G. Whitney.
Drafting of the article: J.E. Sisk.
Critical revision of the article for important intellectual content: J.E. Sisk, W. Whang, J.C. Butler, V.-P. Sneller, C.G. Whitney.
Final approval of the article: J.E. Sisk, W. Whang, J.C. Butler, V.-P. Sneller, C.G. Whitney.
Provision of study materials or patients: J.C. Butler, V.-P. Sneller, C.G. Whitney.
Statistical expertise: W. Whang.
Obtaining of funding: J.E. Sisk, V.-P. Sneller.
Administrative, technical, or logistic support: J.E. Sisk, J.C. Butler, V.-P. Sneller.
Collection and assembly of data: J.E. Sisk, W. Whang, C.G. Whitney.
Sisk JE, Whang W, Butler JC, Sneller V, Whitney CG. Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race. Ann Intern Med. 2003;138:(12):960-968. doi: 10.7326/0003-4819-138-12-200306170-00007
Download citation file:
Published: Ann Intern Med. 2003;138(12):960-968.
Policymakers are increasingly recommending age 50 years as a milestone for interventions to prevent disease (primary prevention) or to screen for asymptomatic disease for which treatment can prevent sickness and death (secondary prevention). Clinical guidelines have advised screening at age 50 years to detect early disease, such as breast and colorectal cancer, but only recently have begun to include vaccinations (1, 2). In 1999, the Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention (CDC), recommended reducing the age for universal influenza vaccination from 65 years to 50 years.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, Vaccines/Immunization, Streptococcal Infections, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only